50
total announcements
ZYDUSLIFE.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 22 Oct 2026
Market Cap
₹1.11 L Cr
P/E (TTM)
24.9
P/E (Forward)
22.7
EPS (TTM)
₹44.87
52W Low
₹835.50
52W High
₹1,232.10
Dividend Yield
0.09%
Beta
0.37
Price / Book
4.1
Debt / Equity
42.3
Revenue (TTM)
₹28,592 Cr
Gross Margin
72.11%
Operating Margin
16.44%
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has partnered with Prolific Machines to scale Prolific's next-generation biologics manufacturing platform to GMP production at Zydus's Emeryville facility.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd will hold a Board Meeting on November 4, 2026, to consider unaudited financial results for the quarter/half year ended September 30, 2026. The trading window will be closed from November 6 to November 8, 2026.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has received an ESG rating of 71 from NSE Sustainability Ratings and Analytics Ltd, categorizing it as a 'leader' for the financial year 2026.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has signed an agreement with the Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka, with a phased investment of over USD 20 million and commercial operations expected to commence in 2028.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has announced that the USFDA inspection of its manufacturing plant at Moraiya, Ahmedabad has concluded with 5 observations. The company will work closely with the USFDA to address these observations.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has announced that the US FDA has accepted for review the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda, marking a significant step towards expanding access to affordable pembrolizumab therapy in the US and Canada.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd announced that its subsidiary Zydus Therapeutics presented new post hoc analysis of Phase 3 EPICS-III trial at ACG 2026, showing greater biochemical response with investigational Saroglitazar compared to placebo across geographic subgroups in PBC.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has issued a certificate under regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities for the quarter ended September 30, 2026.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has partnered with MSN Laboratories Private Limited to launch the first generic version of Adempas (Riociguat Tablets) in the U.S. market, expanding its complex-generics pipeline and commercial reach in the U.S.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has extended the date of closing for its 50:50 joint venture with Sunshine Healthcare Lanka Limited, citing completion of condition precedents. The transaction is now expected to be completed by December 2026.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has announced that the USFDA inspection at its manufacturing plant at SEZ II, Ahmedabad has concluded with one observation, with no data integrity related observations.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has announced that the trading window for its directors and designated persons will be closed from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ending September 30, 2026.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has announced that the USFDA inspection of its pharmacovigilance and post-marketing system at its USA office has concluded with nil observations.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has published a notice in the Financial Express newspaper regarding the loss of share certificates for two shareholders, with a 7-day window for objections before duplicate certificates are issued.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has announced the publication of a notice in the Financial Express newspaper regarding the opening of a special window for transfer and dematerialization of physical securities, as per SEBI Circular No. H0/38113111 (2)2026-MIRSD-P00/1/3750/2026 dated January 30, 2026.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd held its 31st Annual General Meeting on August 11, 2026, through video conferencing, with the Chairman, Pankaj R. Patel, welcoming attendees and introducing the board members and key managerial personnel. The meeting was conducted in accordance with the Companies Act, 2013, and the circulars issued by MCA and SEBI. The company also announced the appointment of Kulin S. Lalbhai as an additional independent director, subject to shareholder approval.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd announced positive topline results from its completed EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg in MASH, achieving its primary endpoint of resolution of steatohepatitis with no worsening of fibrosis.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has incorporated a wholly owned subsidiary, Zydus Global Treasury Centre IFSC Ltd, in Gift City, Gandhinagar, Gujarat.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has been assigned an ESG score of 66 by CRISIL, up from 61, indicating a 'strong' rating.